Noted: Many major pharmaceutical companies are currently studying the concept, according to industry experts. “That’s the promise—that you’ll be able to target a range of things,” says Aseem Ansari, a professor of biochemistry at the University of Wisconsin–Madison who is involved in this area of research. Despite thalidomide’s success, protein degradation so far remains largely untested in humans—and it will probably be several years before early trials in patients can advance enough to prove the approach will work beyond multiple myeloma.
University Communications